Cyclacel Pharmaceuticals Files 8-K Report
Ticker: BGMSP · Form: 8-K · Filed: Apr 26, 2024 · CIK: 1130166
| Field | Detail |
|---|---|
| Company | Cyclacel Pharmaceuticals, INC. (BGMSP) |
| Form Type | 8-K |
| Filed Date | Apr 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-reporting
TL;DR
Cyclacel Pharma filed a routine 8-K, no major news yet.
AI Summary
On April 26, 2024, Cyclacel Pharmaceuticals, Inc. filed an 8-K report. The filing primarily contains information related to the company's corporate structure and financial reporting, with no specific material events or transactions detailed in the provided excerpt.
Why It Matters
This filing indicates routine corporate reporting by Cyclacel Pharmaceuticals, Inc. to the SEC, providing transparency on its operational and financial status.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no immediate indication of significant positive or negative developments.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 (location) — Principal executive offices address
- April 26, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing for Cyclacel Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report current information about the company as required by the Securities Exchange Act of 1934, with the earliest event reported being April 26, 2024.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Cyclacel Pharmaceuticals, Inc.
In which state was Cyclacel Pharmaceuticals, Inc. incorporated?
Cyclacel Pharmaceuticals, Inc. was incorporated in Delaware.
What is the IRS Employer Identification Number for Cyclacel Pharmaceuticals, Inc.?
The IRS Employer Identification Number for Cyclacel Pharmaceuticals, Inc. is 91-1707622.
What is the address of the principal executive offices of Cyclacel Pharmaceuticals, Inc.?
The address of the principal executive offices is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-04-26 17:20:07
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital Ma
Filing Documents
- tm2412831d1_8k.htm (8-K) — 26KB
- 0001104659-24-053101.txt ( ) — 239KB
- cycc-20240426.xsd (EX-101.SCH) — 3KB
- cycc-20240426_def.xml (EX-101.DEF) — 26KB
- cycc-20240426_lab.xml (EX-101.LAB) — 36KB
- cycc-20240426_pre.xml (EX-101.PRE) — 25KB
- tm2412831d1_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. On April 25, 2024, the Board of Directors of Cyclacel Pharmaceuticals, Inc. (the "Company") passed a resolution to suspend payment of the quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock (the "Preferred Stock") scheduled for May 1, 2024. The Board of Directors will continue to evaluate the payment of a quarterly cash dividend on a quarterly basis.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CYCLACEL PHARMACEUTICALS, INC. By: /s/ Paul McBarron Name: Paul McBarron Title: Executive Vice President-Finance, Chief Financial Officer and Chief Operating Officer Date: April 26, 2024